X antigen family member 5Genealiases: CT12.5 · GAGED5 · XAGE-5
Q-omics provides the consensus-scored XAGE5 profile across patient tissues and cancer cell-line models. XAGE5 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, XAGE5 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, XAGE5 RNA expression shows 7,337 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, BRCA, and TGCT as cancer lineages where XAGE5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XAGE5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XAGE5 survival associations across molecular data types. XAGE5 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XAGE5 RNA expression–survival associations across cancer types. High XAGE5 expression shows unfavorable associations in KICH, LIHC, READ, CESC, COAD and STAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for XAGE5 RNA expression.
This table summarizes XAGE5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for XAGE5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XAGE5 shows lower tumor expression in BRCA and higher tumor expression in LIHC. The BRCA box plot shows higher XAGE5 RNA expression in normal versus tumor tissue (log2 FC = −0.054, t-test p = .018).
This table shows molecular features associated with XAGE5 in patient tissues and cancer cell lines. In patient samples, XAGE5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, XAGE5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_NSCLC_LUAD.
